Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to f...
Agile Therapeutics is a forward-thinking women'...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...
At MannKind Corporation (NASDAQ: MNKD), we focu...
Galmed is a clinical-stage biopharmaceutical company focused on the development of...
Galmed is a clinical-stage biopharmaceutical co...
Join the National Investor Network and get the latest information with your interests in mind.